72. Remdesivir vs Standard Care in Patients with Moderate covid-19

BACKGROUND: Remdesivir (RDV) shortens time to recovery time in patients with severe COVID-19. Its effect in patients with moderate COVID-19 remains unclear. METHODS: We conducted an open-label, phase 3 trial (NCT04252664) involving hospitalized patients with confirmed SARS-CoV-2 infection, evidence...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Open Forum Infect Dis
Hlavní autoři: Marty, Francisco M, Malhotra, Prashant, Gottlieb, Robert L, Tashima, Karen T, Galli, Massimo, Chai, Louis Yi Ann, SenGupta, Devi, Hyland, Robert H, Wang, Hongyuan, Zhong, Lijie, Cao, Huyen, Chokkalingam, Anand, Osinusi, Anu, Brainard, Diana M, Brown, Michael, Goikoetxea, Ane Josune, Jain, Mamta, Hui, David Shu Cheong, Bernasconi, Enos, Spinner, Christoph
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2020
Témata:
Poster Abstracts
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7777983/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofaa439.382
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky